Paclitaxel pharmaceutical composition and pharmaceutical preparation, preparation method and application thereof
A solid pharmaceutical preparation, paclitaxel technology, applied in drug combination, drug delivery, pharmaceutical formulations, etc., can solve the problems of paclitaxel slow progress, low solubility, lack of functional salt-forming groups, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0104] The technical solutions of the present invention will be further described below through specific examples. It should be noted that the embodiments are only illustrative, not limiting the protection scope of the present invention. The invention is capable of other embodiments or of being practiced or carried out in various ways.
[0105] All percentages, parts, ratios, etc. herein are by weight unless otherwise indicated.
[0106] Evaluation method for the physical and chemical properties of paclitaxel pharmaceutical composition
[0107] Powder X-ray diffraction (X-RD): take appropriate amount of paclitaxel bulk drug, physical mixture, and contrast composition or pharmaceutical composition of the present invention respectively, under the condition of Cu target, 45kv voltage, 45mA electric current, record their powder X-ray diffraction pattern (D8ADVANCE X-ray diffractometer manufactured by BRUKER).
[0108] Determination of apparent solubility: Weigh the excess pharm...
Embodiment 1
[0142] Embodiment 1 paclitaxel-HPMCAS pharmaceutical composition / physical mixture (the present invention)
[0143] 1. Preparation
[0144] 1) Composition:
[0145] The specific composition of the paclitaxel-HPMCAS pharmaceutical composition / physical mixture is shown in Table 2-1.
[0146] 2) Preparation:
[0147] Paclitaxel-HPMCAS pharmaceutical composition: according to the specific composition and dosage in Table 2-1, paclitaxel and carrier material HPMCAS (specifically AS-M) and optionally Add TPGS respectively into the mixer and mix evenly, and then feed into the hopper of a co-rotating twin-screw extruder (Omicron 12 from India Steer Company); or directly feed the above ingredients according to the specific composition and dosage in Table 2-1 Feed into the hopper of the co-rotating twin-screw extruder. Set the melting temperature of the co-rotating twin-screw extruder to about 140°C, and the screw speed to about 150rpm, cool, crush, and sieve the extruded product a...
Embodiment 2
[0170] The above tests show that, compared with the paclitaxel bulk drug and Comparative Example 1, the pharmaceutical composition of the present invention can significantly improve the solubility and dissolution rate of paclitaxel. Especially when further adding to the pharmaceutical composition of the present invention During TPGS, the dissolution rate of the pharmaceutical composition was greatly improved, indicating that the carrier material HPMCAS and TPGS has a synergistic solubilizing effect on pharmaceutical compositions. The pharmacokinetic research of embodiment 2 paclitaxel-HPMCAS pharmaceutical composition of the present invention
[0171] 1. Test preparation
[0172] Test preparation:
[0173] Tablets of paclitaxel-HPMCAS compositions 2-4 prepared according to Example 1.
[0174] Comparative preparation:
[0175] ORAXOL TM : Paclitaxel oral solution (ClinicalTrials.gov, clinical trial number NCT01967043) used in Phase I clinical trials, wherein every ml of...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


